China-based Jiangsu Kanion Pharmaceutical Co., Ltd (SHA: 600557) has announced receiving separate clinical trial approvals from the National Medical Products Administration (NMPA) for its two Category 1 products: KYHY2302 cream for mild to moderate plaque psoriasis and KYHY2303 tablets for recurrent or refractory malignant hematological tumors.
KYHY2302 Cream for Plaque Psoriasis
KYHY2302, a phosphodiesterase-4 (PDE4) small molecule inhibitor co-developed by the Shanghai Institute of Materia Medica (SIMM) of the Chinese Academy of Sciences (CAS), is indicated for the treatment of mild to moderate plaque psoriasis. Preclinical cell and animal level pharmacological studies have confirmed that KYHY2302 is a highly selective PDE4 inhibitor with excellent in vitro immunosuppressive activity and in vivo psoriasis therapeutic activity. Toxicological studies have shown that KYHY2302 is safe, and pharmacokinetic studies have demonstrated its excellent pharmacokinetic properties.
KYHY2303 Tablets for Malignant Hematological Tumors
KYHY2303, an SHP2 allosteric inhibitor co-developed by SIMM and other institutes in China, is designed for the treatment of recurrent or refractory malignant hematological tumors such as acute myeloid leukemia (AML). Non-clinical pharmacological studies have shown that KYHY2303 exhibits excellent therapeutic effects in different AML pharmacological models. Non-clinical pharmacological and toxicological studies have also demonstrated its good safety profile.-Fineline Info & Tech
